ライフサイエンスコーパス: cabotegravir

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 andomly allocated in a 1:1:1:1 ratio to oral cabotegravir 10 mg once a day, 30 mg once a day, 60 mg o

2 esults lend support to our selection of oral cabotegravir 30 mg once a day for further assessment.

3 infected with HIV-1 initially received oral cabotegravir 30 mg plus abacavir-lamivudine 600-300 mg o

4 Participants received oral cabotegravir 30 mg tablets or matching placebo once dail

5 rilpivirine at 4-week intervals (long-acting cabotegravir 400 mg plus rilpivirine 600 mg; two 2 mL in

6 d at week 48, and 137 (76%; 69-82) receiving cabotegravir (41 [68%; 57-80], 45 [75%; 64-86], and 51 [

7 injections) or 8-week intervals (long-acting cabotegravir 600 mg plus rilpivirine 900 mg; two 3 mL in

8 hree intramuscular injections of long-acting cabotegravir 800 mg or saline placebo at 12 week interva

9 Cabotegravir and rilpivirine are antiretroviral drugs in

10 ther investigation of long-acting injectable cabotegravir as an alternative to orally administered pr

11 gimen consisting of their randomly allocated cabotegravir dose plus oral rilpivirine 25 mg or continu

12 roup 24 weeks after the final injection when cabotegravir exposure was well below the protein-binding

13 as higher in participants in the long-acting cabotegravir group (n=75 [80%]) than in those in the pla

14 up during the injection phase and one in the cabotegravir group 24 weeks after the final injection wh

15 87 (82%) participants in the cabotegravir group and 20 (95%) participants in the plac

16 were the main reasons for withdrawal in the cabotegravir group.

17 24, 149 (82%; 95% CI 77-88) patients in the cabotegravir groups (48 [80%; 70-90], 48 [80%; 70-90], a

18 nd treated, 156 (86%) of 181 patients in the cabotegravir groups (52 [87%] of 60, 51 [85%] of 60, and

19 Six (3%) patients in the cabotegravir groups (one [2%], one [2%], and four [7%] p

20 After patients in the cabotegravir groups were changed over from dual NRTIs to

21 tand the factors associated with long-acting cabotegravir (GSK1265744 LAP) pharmacokinetic variabilit

22 Cabotegravir (GSK1265744) is an HIV-1 integrase strand t

23 he HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) was well tolerated, both alone

24 ability, and pharmacokinetics of long-acting cabotegravir injections in healthy men not at high risk

25 andomly assigned 127 participants to receive cabotegravir (n=106) or placebo (n=21); 126 (99%) partic

26 d for 96 weeks, but not to the assignment of cabotegravir or efavirenz.

27 central randomisation schedules, to receive cabotegravir or placebo.

28 After a 20-week induction period on oral cabotegravir plus abacavir-lamivudine, patients with vir

29 0 mg; two 3 mL injections) or continued oral cabotegravir plus abacavir-lamivudine.

30 tramuscular dosing regimens relative to oral cabotegravir plus abacavir-lamivudine.

31 Cabotegravir plus dual NRTI therapy had potent antiviral

32 ssigned (2:2:1) to intramuscular long-acting cabotegravir plus rilpivirine at 4-week intervals (long-

33 g combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or every 8 w

34 The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 v

35 As a two-drug maintenance therapy, cabotegravir plus rilpivirine provided antiviral activit

36 We assessed cabotegravir plus rilpivirine, as a two-drug oral antire

37 ts and investigators were masked to doses of cabotegravir received for 96 weeks, but not to the assig

38 ted adverse events were reported by 93 (51%) cabotegravir-treated patients (28 [47%], 32 [53%], and 3

39 derate injection-site reactions, long-acting cabotegravir was well tolerated with an acceptable safet

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。